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Abstract
Background: In patients undergoing cardiac surgery, a reduced preoperative left ventricular ejection fraction (LVEF)
is common and is associated with a worse outcome. Available outcome data for these patients address specific
surgical procedures, mainly coronary artery bypass graft (CABG). Aim of our study was to investigate perioperative
outcome of surgery on patients with low pre-operative LVEF undergoing a broad range of cardiac surgical
procedures.
Methods: Data from patients with pre-operative LVEF ≤40 % undergoing cardiac surgery at a university hospital
were reviewed and analyzed. A subgroup analysis on patients with pre-operative LVEF ≤30 % was also performed.
Results: A total of 7313 patients underwent cardiac surgery during the study period. Out of these, 781 patients
(11 %) had a pre-operative LVEF ≤40 % and were included in the analysis. Mean pre-operative LVEF was 33.9 ± 6.
1 % and in 290 patients (37 %) LVEF was ≤30 %. The most frequently performed operation was CABG (31 % of
procedures), followed by mitral valve surgery (22 %) and aortic valve surgery (19 %). Overall perioperative mortality
was 5.6 %. Mitral valve surgery was more frequent among patients who did not survive, while survivors underwent
more frequently CABG. Post-operative myocardial infarction occurred in 19 (2.4 %) of patients, low cardiac output
syndrome in 271 (35 %). Acute kidney injury occurred in 195 (25 %) of patients. Duration of mechanical ventilation
was 18 (12–48) hours. Incidence of complications was higher in patients with LVEF ≤30 %. Stepwise multivariate
analysis identified chronic obstructive pulmonary disease, pre-operative insertion of intra-aortic balloon pump, and
pre-operative need for inotropes as independent predictors of mortality among patients with LVEF ≤40 %.
Conclusions: We confirmed that patients with low pre-operative LVEF undergoing cardiac surgery are at higher risk
of post-operative complications. Cardiac surgery can be performed with acceptable mortality rates; however, mitral
valve surgery, was found to be associated with higher mortality rates in this population. Accurate selection of
patients, risk/benefit evaluation, and planning of surgical and anesthesiological management are mandatory to
improve outcome.
Keywords: Cardiac surgery, Left ventricular dysfunction, Low cardiac output syndrome, Mitral valve surgery,
Left ventricular ejection fraction, Coronary artery bypass graft, Intensive care, Anesthesia, Mortality
* Correspondence: landoni.giovanni@hsr.it
1Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific
Institute, Via Olgettina 60, 20132 Milan, Italy
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Pieri et al. BMC Anesthesiology  (2016) 16:97 
DOI 10.1186/s12871-016-0271-5
Background
Low preoperative left ventricular ejection fraction
(LVEF) is common in patients undergoing cardiac
surgery, especially those scheduled for coronary artery
bypass graft (CABG) surgery. Despite improvements in
medical therapy and surgical techniques, management of
patients with moderate or severe left ventricular dys-
function undergoing cardiac surgery remains challenging
[1, 2]. As known, patients with low LVEF are at a higher
risk for postoperative complications and mortality after
cardiac surgery [1]. Therefore, an early recognition of
patients at risk for a worse outcome plays a pivotal role
in the decision making process, allowing the prompt
institution of an adequate support [3]. Several periopera-
tive variables have been purposed as predictors of
mortality [4–8], including acute renal failure [9] and
pneumonia [10], and are currently applied in everyday
clinical practice [10] to identify patients at higher risk.
Low EF is per se the strongest predictor of a poor out-
come and is included in all scoring system currently
available. Indeed, low LVEF is associated to postopera-
tive low cardiac output syndrome (LCOS), need for ino-
tropic support [11, 12], acute renal failure [9, 13, 14],
respiratory failure [1], pneumonia [10], atrial fibrillation
[15], stroke, sepsis or endocarditis, deep sternal wound
infection, bleeding requiring reoperation and gastro-
intestinal bleeding [1]. However, the outcome after car-
diac surgery has improved over time leading to a
significant decrease of the performance of the currently
available scores. There is a currently unmet need for
more sophisticated preoperative predictive parameters,
which may help to further stratify patients with impaired
cardiac function, that are nevertheless candidate to
undergo cardiac surgery. Indeed several biological and
procedural variables, the constant evolution in both
practice of surgery and perioperative medicine, the vol-
ume of activity of the hospital should somehow be taken
into consideration [16], together with EF.
Aim of the present study was therefore to assess the
mortality rate in high-risk patients with low EF (<40 %)
undergoing cardiac surgery and to identify the risk fac-
tors associated with a worse outcome in a national refer-
ral cardiac surgery center with a high volume of surgical
activity.
Methods
The study was performed in accordance with the Declar-
ation of Helsinki and its amendments. After approval by
the local Ethical Committee (OSR Ethical Committee, 38
AN CCH 31-10-2013) data from all patients with LVEF ≤
40 % who underwent cardiac surgery at San Raffaele
Scientific Institute over a 6 years’ period were collected.
No specific written consent was obtained for this retro-
spective observational study since all patients’ data were
anonymized and de-identified prior to analysis. However,
all patients signed a written consent for the use of their
data for scientific purposes.
All patients underwent transthoracic and/or transeso-
phagel echocardiography as part of routine pre-operative
assessment. The examination was performed by a
cardiologist trained in perioperative echocardiography,
usually the day before surgery. The threshold for data
analysis (40 %) followed the 2015 recommendation from
the American Society of Echocardiography and the
European Association of Cardiovascular Imaging [17],
which further identified an LVEF value of 30 % as the
cut off of severely depressed cardiac function.
All patients underwent cardiac surgery under general
anesthesia and at the end of the surgery were transferred
to the intensive care unit (ICU). A standard premedica-
tion with morphine 0.1 mg/kg subcutaneously and
scopolamine 0.25 mg intramuscularly one hour before
surgery was administered. General anesthesia was in-
duced with an intravenous bolus of propofol, fentanyl
and muscle relaxant and maintained with fentanyl,
muscle relaxants and either halogenates or propofol (or
both). An intravenous infusion of tranexamic acid was
administered intraoperatively: 1 g in 20 min followed by
a 400 mg/h infusion. A temperature of 32–34 °C was
maintained during cardiopulmonary bypass (CPB) and
myocardial protection during aortic cross clamping was
performed by anterograde and/or retrograde cold cardi-
oplegia. Unfractionated heparin (at a starting dose of
3 mg/kg) was administered in order to maintain an acti-
vated clotting time (ACT) of more than 480 s during
CPB. Heparin was reversed with protamine in a 1:1 ratio.
The target mean arterial pressure during CPB was
65 mmHg.
After surgery, patients were transferred to the ICU
under sedation with propofol. Weaning from mechanical
ventilation was started, in the absence of hemodynamic
instability and major bleeding, as soon as normothermia
and an adequate level of consciousness were achieved.
Antibiotic prophylaxis was performed with intravenous
cephazolin. Standard therapy also included hydration,
antiacids and diuretics, as well as inotropic drugs and
mechanical circulatory support devices when required
by the hemodynamic conditions.
Myocardial infarction was defined according to the
Consensus Conference for the Universal Definition of
Myocardial Infarction [18]. Low cardiac output syn-
drome was defined as arterial hypotension (systolic
blood pressure <100 mmHg) with signs of organ hypo-
perfusion (decreased urine output, lactic acidosis,..) and
cardiac index below 2 l/min/m2 despite adequate fluid
replacement. Cardiogenic shock was defined according
to the IABP-SHOCK Trial [19]. Acute kidney injury
(AKI) was diagnosed in the presence of an increase in
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serum creatinine of more than 50 % or a decrease in the
glomerular filtration rate (GFR) of more than 25 % as
compared to preoperative values [20]. The Cockroft-Gault
equation was used to estimate GFR [21]. Age-Creatinine-
Ejection Fraction (ACEF) score was calculated [22]. We
defined “redo” a patient who had already undergone ster-
notomy for cardiac surgery. Postoperative atrial fibrillation
(AF) was defined as a new onset of AF requiring pharma-
cological or electrical cardioversion during the ICU stay.
Statistical analysis
Data were stored electronically and analyzed using the
9.2 version of the SAS software (SAS Institute Inc., Cary,
NC, USA). Categorical variables are reported as numbers
(percent), whereas continuous variables are expressed as
mean ± standard deviation (SD) or as median (interquar-
tile range) according to the Kolmogorov-Smirnov test.
The Fisher’s test was used to calculate p values between
two groups for categorical variables. Multiple logistic re-
gression was used to identify independent predictors of
mortality. A stepwise selection method was used for
death (dichotomous variable), with COPD, Pre-operative
intraaortic balloon pump (IABP), Pre-operative ino-
tropes for patients with FE ≤ 40 % and with Pre-
operative renal failure and Mitral valve surgery for pa-
tients with FE ≤ 30 %. The area under the ROC curves of
the two predictive models was also calculated.
Results
Out of 7357 patients undergoing cardiac surgery in the
study period, 7313 had data on preoperative LVEF. Of
these, 781 patients (11 %) had preoperative LVEF ≤ 40 %
and were included in the study. Baseline characteristics,
comorbidities, type of operation and intraoperative man-
agement of the study population are reported in Table 1.
Mean age was 65.4 ± 10.3 years, and 76 % of patients
were male. Mean preoperative LVEF was 33.9 ± 6.1 %.
The most common intervention performed was
CABG, followed by mitral valve surgery (either replace-
ment or repair), and aortic valve replacement. Three-
hundred sixty six patients (47 %) underwent combined
surgical procedures.
Postoperative outcomes are reported in Table 2.
Among patients with LVEF ≤ 40 %, mortality was 5.6 %
and was consistent with preoperative predictions (mean
EuroSCORE was six and mean ACEF score was 5.59).
Mortality rates for the different LVEF classes are pre-
sented in Fig. 1. As expected, mortality risk increases as
LVEF decreases. In the study cohort, mitral valve surgery
was the most common operation performed among
non-survivors compared with survivors (32 vs. 22 %, p =
0.009). Conversely, isolated CABG was the most com-
mon operation performed among survivors (16 vs. 5.4 %,
p = 0.02). Survivors had significantly shorter ICU length
of stay (LOS) (3 vs. 12 days, p < 0.001), hospital LOS (7
vs. 15.5 days, p < 0.001), duration of mechanical ventila-
tion (18 vs. 88 h, p < 0.001), lower need for renal replace-
ment therapy (RRT) (3.3 % vs. 50 %, p < 0.001), lower
troponin peak (7.83 vs. 21.32, p < 0.001), and less need
for blood transfusions (31 vs. 70 %, p < 0.001). Regarding
postoperative complications, patients who died had a
significantly higher rate of LCOS (75 vs. 32 %, p < 0.001),
cardiogenic shock (55 vs. 3.4 %, p < 0.001), AKI (86 vs.
21 %, p < 0.001), sepsis (11 vs. 2.7 %, p = 0.01), and severe
pulmonary dysfunction (27 vs. 2.7 %, p < 0.001).
Multivariate analysis identified the following independ-
ent predictors of mortality in patients with LVEF ≤ 40 %:
history of chronic obstructive pulmonary disease
(COPD) (odds ratio [OR] 3.419, 95 % confidence interval
[CI] 1.266–9.238, p = 0.015), preoperative use of IABP
(OR 3.335, 95 % CI 1.258–8.839, p = 0.015), and need for
inotropes prior to surgery (OR 13.595, 95 % CI 2.852–
64.808, p = 0.001) (Table 3). The area under the ROC
curve was 0.61.
Two hundred and ninety patients (37.13 %) had a pre-
operative LVEF below 30 % (mean, 26.9 ± 3.8 %). Base-
line and outcomes data of these patients are shown as
supplementary material (Additional file 1: Tables S1 and
S2 respectively). Mean age (65.4 ± 9.9 years) was similar
to the entire cohort with a prevalence of male.
Although the mortality rate in patients with LVEF ≤
30 % was higher (7.6 %) than the overall study popula-
tion it was lower than expected (mean EuroSCORE = 7;
mean ACEF mortality risk = 10.19). One hundred-sixty
patients (48 %) underwent combined surgery.
The most common operation performed in patients
with LVEF ≤ 30 %, who did not-survive was mitral valve
surgery (37 % of non-survivors vs. 21 % of survivors, p =
0.005). On the contrary, all the 59 patients (12 %) with
LVEF <30 % who underwent isolated CABG survived.
Unlike the whole cohort of low LVEF patients, in those
with LVEF ≤ 30 % there was no statistically significant
difference between survivors and non-survivors for the
rate of wound infections, mediastinitis, sepsis, serum
creatinine peak, hospital LOS, and length of mechanical
ventilation. Moreover, no gastrointestinal complications
occurred in this subgroup.
The rate of perioperative myocardial infarction was
not statistically different between survivors and non-
survivors, both in the entire study population and in the
subgroup of patients with LVEF ≤ 30 %.
The only two predictors independently associated to
mortality in the sub-group of patients with an EF <30 %
were preoperative renal failure (defined as pre-operative
eGFR < 90 mL/min) and mitral valve surgery (OR 6.845,
95 % CI 1.841–25.45, p = 0.004 and OR 5.244, 95 % CI
1.290–21.322, p = 0.021, respectively) (Table 3). The area
under the ROC curve was 0.53.
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Table 1 Baseline and intra-operative characteristics of patients with ejection fraction ≤40 % who underwent cardiac surgery: com-
parisons between survivors and dead patients
Variable Total (N = 781) Survivors (N = 737) Dead (N = 44) P-value
Preoperative characteristics
Gender (Male), n 597 (76 %) 569 (77 %) 28 (64 %) 0.04
Age, years 65.4 ± 10.3 65.3 ± 10.4 68.4 ± 9.4 0.0575
Height, cm 169.6 ± 8.1 169.7 ± 8.0 167.6 ± 9.4 0.2
Weight, kg 73.7 ± 13.4 73.8 ± 13.3 71.2 ± 14.6 0.2
BMI 25.6 ± 4.0 25.6 ± 4.0 25.4 ± 4.4 0.8
Comorbidity
> COPD, n 235 (30 %) 210 (28 %) 25 (57 %) <0.001
> Preoperative EF, % 33.9 ± 6.1 34.0 ± 6.1 31.8 ± 6.0 0.01
> Preoperative EF≤ 40 %, n 781 (100 %)
> Preoperative EF≤ 30 %, n 290 (37 %)
> Peripheral vasculopathy, n 196 (25 %) 183 (25 %) 13 (30 %) 0.5
> Arterial hypertension, n 423 (54 %) 402 (55 %) 21 (48 %) 0.4
> Type II diabetes mellitus, n 159 (20 %) 151 (20 %) 8 (18 %) 0.7
> Carotid stenosis, n 71 (9.1 %) 68 (9.2 %) 3 (6.8 %) 0.8
> Angina, n 112 (14 %) 104 (14 %) 8 (18 %) 0.5
> Previous AMI, n 243 (31 %) 227 (31 %) 16 (36 %) 0.4
> Previous TIA or stroke, n 61 (7.8 %) 58 (7.9 %) 3 (6.8 %) 0.99
> Previous vascular surgery, n 37 (4.7 %) 37 (5 %) 0 (0 %) 0.3
> Standard EuroSCORE 6 (4–8) 6 (4–8) 8 (6–10) <0.001
> ACEF score 2.08 (1.77–2.47) 2.06 (1.75–2.44) 2.43 (2.08–3.16) <0.001
> ACEF risk 5.59 (3.89–8.78) 5.46 (3.81–8.56) 8.45 (5.61–18.52) <0.001
> Endocarditis, n 22 (2.8 %) 20 (2.7 %) 2 (4.5) 0.4
> Creatinine clearance, ml/h 65.1 (49.2–82.6) 65.67 (50.23–83.33) 49.1 (39.66–69.27) 0.002
> Chronic renal failure, n 149 (19 %) 134 (18 %) 15 (34 %) 0.009
> Dialysis, n 13 (1.7 %) 12 (1.6 %) 1 (2.3 %) 0.5
NYHA 0.003
> I 51 (6.5 %) 51 (6.9 %) 0 (0 %)
> II 208 (27 %) 201 (27 %) 7 (16 %)
> III 276 (35 %) 267 (36 %) 9 (20 %)
> IV 43 (5.5 %) 36 (4.9 %) 7 (16 %)
Timing of surgery 0.2
> Emergency, n 18 (2.3 %) 16 (2.2 %) 2 (4.5 %)
> Urgency, n 129 (17 %) 119 (16 %) 10 (23 %)
> Election, n 634 (81 %) 602 (82 %) 32 (73 %)
Redo surgery, n 81 (10 %) 73 (9.9 %) 8 (18 %) 0.08
Preoperative IABP, n 135 (17 %) 121 (16 %) 14 (32 %) 0.009
Preoperative inotropes, n 17 (2.2 %) 11 (1.5 %) 6 (14 %) <0.001
Chronic therapy
> Antiplatelets, n 267 (34 %) 258 (35 %) 9 (20 %) 0.048
> Diuretics, n 503 (64 %) 470 (64 %) 33 (75 %) 0.13
> Beta-blockers, n 365 (47 %) 353 (48 %) 12 (27 %) 0.008
> Antibiotics, n 38 (4.9 %) 34 (4.6 %) 4 (9.1 %) 0.16
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As mitral valve surgery was found to be associated
with mortality, we performed a further comparison
between patients who had undergone isolated mitral
valve versus isolated CABG surgery. The mortality rate
of patients with EF ≤ 40 % (Table 1) was not different
between these two groups (p = 0.081), but reached
statistical significance in patients with EF ≤30 % (Additional
file 1: Table S1).
Baseline descriptive data of patients undergoing mitral
valve surgery are reported in Additional file 1: Table S3.
Discussion
Data from this large cohort of cardiac surgical patients
confirmed that low LVEF still represent a common issue
in this setting, affecting more than 10 % of patients. This
population represents a group at higher surgical risk due
to the greatly reduced cardiovascular reserve; for this
reason, a comprehensive and insightful preoperative risk
stratification, beyond the LVEF value itself, is strongly
recommended. In this sense, our experience may add
new clues to be implemented into clinical practice.
Table 1 Baseline and intra-operative characteristics of patients with ejection fraction ≤40 % who underwent cardiac surgery: com-
parisons between survivors and dead patients (Continued)
> Calcium channel blockers, n 128 (16 %) 121 (16 %) 7 (16 %) 0.9
> Nitrates, n 217 (28 %) 205 (28 %) 12 (27 %) 0.9
> ACE inhibitors, n 496 (64 %) 473 (64 %) 23 (52 %) 0.11
> Oral anticoagulants, n 135 (17 %) 130 (18 %) 5 (11 %) 0.4
> Heparin, n 61 (7.8 %) 57 (7.7 %) 4 (9.1 %) 0.8
Creatinine, mg/dl 1.2 ± 0.9 1.2 ± 0.9 1.5 ± 1.1 0.004
Bilirubin, mg/dl 0.8 (0.57–1.1) 0.8 (0.57–1.04) 0.94 (0.63–1.4) 0.1
Surgical interventions
CABG, n 390 (31 %) 373 (31 %) 17 (23 %) 0.12
> Isolated CABG, n 189 (15 %) 185 (16 %) 4 (5.4 %) 0.02
Mitral valve surgery, n 282 (22 %) 258 (22 %) 24 (32 %) 0.009
> Isolated mitral valve surgery, n 90 (7.1 %) 84 (7.1 %) 6 (8.1 %) 0.7
> Mitral valve replacement, n 126 (10 %) 117 (9.9 %) 9 (12 %) 0.4
> Mitral valve repair, n 156 (12 %) 141 (12 %) 15 (20 %) 0.02
Aortic valve surgery, n 241 (19 %) 227 (19 %) 14 (19 %) 0.9
> Isolated aortic valve surgery, n 81 (6.4 %) 76 (6.4 %) 5 (6.8 %) 0.8
> Aortic valve replacement, n 241 (19 %) 227 (19 %) 14 (19 %) 0.9
> Aortic valve repair, n 1 (0.08 %) 1 (0.08 %) 0 (0 %) 0.99
Tricuspid valve surgery, n 96 (7.6 %) 91 (7.7 %) 5 (6.8 %) 0.99
> Isolated tricuspid valve surgery, n 3 (0.24 %) 3 (0.25 %) 0 (0 %) 0.99
> Tricuspid valve replacement, n 6 (0.48 %) 6 (0.51 %) 0 (0 %) 0.99
> Tricuspid valve repair, n 90 (7.1 %) 85 (7.2 %) 5 (6.8 %) 0.99
Pulmonic valve surgery, n 1 (0.08 %) 1 (0.08 %) 0 (0 %) 0.99
> Isolated pulmonic valve surgery, n 1 (0.08 %) 1 (0.08 %) 0 (0 %) 0.99
Surgery on ascending aorta, n 83 (6.6 %) 76 (6.4 %) 7 (9.5 %) 0.2
> Isolated surgery on ascending aorta, n 6 (0.48 %) 6 (0.51 %) 0 (0 %) 0.99
Left ventricle surgery, n 77 (6.1 %) 76 (6.4 %) 1 (1.4 %) 0.11
> Isolated left ventricle surgery, n 12 (0.95 %) 12 (1 %) 0 (0 %) 0.99
Intraoperative management
CPB, n 696 (91 %) 656 (89 %) 40 (91 %) 0.4
Duration of aortic cross clamping, min 61 (48–78) 61 (47–78) 69.5 (51–78) 0.3
Duration of CPB, min 85 (65–102) 84 (65–101) 95 (70–114) 0.3
ACEF age-creatinine-ejection fraction, AMI acute myocardial infarction, BMI body mass index, CABG coronary artery bypass graft, COPD chronic obstructive pulmonary
disease, CPB cardiopulmonary bypass, EF ejection fraction, IABP intra-aortic balloon pump, NYHA New York Heart Association, TIA transient ischemic attack
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In the overall cardiac surgical population, CABG is the
most frequently performed operation [5, 23], and ische-
mic cardiomyopathy is the most frequent cause of heart
failure associated to a reduced EF [24]. Therefore, most
cardiac surgery studies have been led on patients with
low LVEF undergoing CABG. On the contrary, very few
studies have investigated the outcome of patients with
low EF undergoing valve surgery [25–27]. As observed
by Hamad et al, the prevalence of low EF is as high as
20 % in patients undergoing CABG [2], while the
percentage decrease to 10–15 % in patients undergoing
valve surgery [25]. To best of our knowledge this is the
first study in which a large heterogeneous population
with an EF below 40 % undergoing predominantly valve
cardiac surgery in a high volume hospital has been in-
vestigated. The percentage of patients with pre-operative
EF below 40 % was 11 %, with one-third of patients
undergoing CABG, and more than 40 % who underwent
valve surgery. The vast majority of studies in patients
with low EF undergoing CABG has shown a higher
perioperative risk and a better survival after myocar-
dial revascularization. In this setting the long-term
benefits clearly overcome an increased peri-operative
mortality [28].
On the contrary, there are no conclusive data on the
perioperative risk of patients with low EF undergoing
valve surgery. The assessment of the perioperative risk
in this kind of patients is of particular relevance for both
the surgical planning and the intra- and postoperative
management. Furthermore, the surgical correction of
different valve defects has different impact on early post-
operative ventricular function and outcome [29, 30].
Table 2 Post-operative complications and outcome data of patients with ejection ≤40 % who underwent cardiac surgery:
comparisons between survived and dead patients
Variable Total (N = 781) Survived (N = 737) Dead (N = 44) P-value
Post-operative complications
Post-operative AMI, n 19 (2.4 %) 17 (2.3 %) 2 (4.5 %) 0.3
Post-operative peak troponin value, ng/ml 8.03 (4.4–15) 7.83 (4.3–14.35) 21.32 (8.07–29.73) <0.001
Post-operative AF, n 202 (26 %) 191 (26 %) 11 (25 %) 0.9
LCOS, n 271 (35 %) 238 (32 %) 33 (75 %) <0.001
Inotropes more than 48 h, n 233 (30 %) 204 (28 %) 29 (66 %) <0.001
Cardiogenic shock, n 49 (6.3 %) 25 (3.4 %) 24 (55 %) <0.001
Post-operative peak creatinine value, mg/dl 1.3 ± 0.9 1.3 ± 0.9 1.5 ± 1.1 0.004
AKI, n 195 (25 %) 157 (21 %) 38 (86 %) <0.001
RRT, n 46 (5.9 %) 24 (3.3 %) 22 (50 %) <0.001
Bleeding in the first 12 postoperative hours, ml 280 (200–400) 280 (200–400) 260 (180–425) 0.9
Total post-operative bleeding, ml 460 (300–720) 460 (300–720) 585 (455–735) 0.2
Need for blood products transfusion, n 263 (34 %) 232 (31 %) 31 (70 %) <0.001
RBC transfusions, n of units per patient 0 (0–1) 0 (0–1) 3 (0–6.5) <0.001
FFP transfusions, n of units per patient 0 (0–0) 0 (0–0) 0 (0–3) <0.001
PLT transfusions, n of units per patient 0 (0–0) 0 (0–0) 0 (0–0.5) <0.001
Neurological damage type 1, n 16 (2 %) 14 (1.9 %) 2 (4.5 %) 0.2
Neurological damage type 2, n 22 (2.8 %) 19 (2.6 %) 3 (6.8 %) 0.12
Severe pulmonary dysfunction, n 32 (4.1 %) 20 (2.7 %) 12 (27 %) <0.001
Tracheostomy, n 27 (3.5 %) 12 (1.6 %) 15 (34 %) <0.001
Need for re-intubation, n 23 (2.9 %) 13 (1.8 %) 10 (23 %) < 0.001
Sepsis, n 25 (3.2 %) 20 (2.7 %) 5 (11 %) 0.01
Mediastinitis, n 6 (0.77 %) 3 (0.41 %) 3 (6.8 %) 0.003
Outcome data
Duration of MV, hours 18 (12–48) 18 (12–43) 88 (34–288) <0.001
ICU stay, days 3 (1–5) 3 (1–5) 12 (4–19) <0.001
Hospital stay, days 7 (5–11) 7 (5–11) 15.5 (8–24) <0.001
Death, n 44 (5.6 %)
AF atrial fibrillation, AKI acute kidney injury, AMI acute myocardial infarction, FFP fresh frozen plasma, ICU intensive care unit, LCOS low cardiac output syndrome,
MV mechanical ventilation, PLT platelets, RBC red blood cells, RRT renal replacement therapy
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The main result of the present study is that, even in
patients with valve disease and impaired EF, cardiac sur-
gery can be performed with acceptable mortality rates
Namely, the mortality rate in patients with LVEF ≤ 40 %
was 5.6 %, while in the subgroup of patients with LVEF ≤
30 % was 7.6 %. These findings are slightly better than
those reported which range between 3 and 10 % in
CABG [1, 2, 31] and valve surgery [25–27]. In our high
surgery volume tertiary care center the mortality rate is
better in patients with the highest degree of ventricular
dysfunction (LVEF ≤ 30 %) compared to previous studies,
which report a mortality rate as high as 7–10 % [2, 27].
Our results confirm that, in patients with a reduced
LVEF (especially in those with LVEF ≤ 30 %), mitral valve
surgery is associated with greater risk of an adverse out-
come compared to isolated CABG. The prognosis might
even be poorer when CABG is associated to mitral valve
surgery [5, 32]. In fact, the mitral valve repair and
replacement are associated to the highest risk of early
postoperative LCOS due to the afterload mismatch, the
highest troponin I release [33] and the highest preopera-
tive risk of death [34–37]. Notably, LVEF in the context
of moderate-severe and severe mitral regurgitation can-
not be relied upon to describe LV systolic function, since
part of the left ventricular stroke volume is directed
backward (towards the left atrium) and does not contrib-
ute to systemic perfusion [38]. Furthermore, the reduc-
tion of EF in these patients might often be caused by
ischemic cardiomyopathy. In a recent sub-analysis of the
Surgical Treatment for Ischemic Heart Failure (STICH)
trial, the presence of severe mitral regurgitation was
found to be a predictor of 30-day mortality in patients
with left ventricular dysfunction undergoing CABG.
Interestingly, concomitant mitral valve surgery was asso-
ciated with better 30-day survival as compared with no
mitral valve surgery [31]. Although results from the
STICH trial have been challenged by a recent multicen-
ter RCT by Smith and colleagues [39], it should be
highlighted that these latter study did not focus on
patients with reduced LVEF and mortality was not the
primary endpoint in the RCT [39]. Treatment strategies for
secondary mitral regurgitation are still a matter of debate,
with available studies giving conflicting results [40] and
current guidelines providing only weak recommendations
Fig. 1 Mortality in the different classes of ejection fraction
Table 3 Independent predictors of mortality (stepwise multivariate analysis)
Variable Odds ratio 95 % Confidence interval P-value
LVEF ≤40 %
COPD 3.419 1.266 9.238 0.0153
Pre-operative IABP 3.335 1.258 8.839 0.0154
Pre-operative inotropes 13.595 2.852 64.808 0.0011
LVEF ≤30 %
Pre-operative renal failure 6.845 1.841 25.450 0.0041
Mitral valve surgery 5.244 1.290 21.322 0.0206
COPD chronic obstructive pulmonary disease, IABP intra-aortic balloon pump
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[41, 42]. Therefore, optimal management of these patients
requires both accurate evaluation and risk stratification and
a thorough discussion with the patient of the possible risks
and benefits.
In patients with EF < 40 %, mitral valve surgery,
preoperative IABP use and need for inotropes, COPD
and chronic kidney disease were identified as inde-
pendent predictors of mortality. The use of pre-
operative IABP and inotropes are markers of severity
illness rather than primary cause of a worse outcome.
Zangrillo et al. have recently shown indeed that IABP
improves the outcomes in high risk patients undergo-
ing CABG [43].
It is not surprising that the need of inotropes prior to
surgery is the strongest predictors of mortality. Chronic
kidney disease and COPD are well known risk factors
for both short- and long-term morbidity and mortality
after cardiac surgery [44–47]. Our findings clearly show
how these conditions acquire an even more considerable
relevance in patients who also have a reduced LV
function. In the present study the rate of postoperative
complications is higher than previously reported in
literature. In particular compared with data from recent
large studies led in a general cardiac surgical population
[48, 49], in this high risk population with low EF we
found a higher rate of postoperative AKI, AF and LCOS
[36, 37]. On the contrary, we observed a lower rate of
myocardial infarction. A possible explanation is that
postoperative myocardial infarction after cardiac surgery
may be related to inaccurate myocardial protection peri-
operative hemodynamic instability, a post-operative pro-
thrombotic state complexity of coronary revasculariza-
tion, surgical technical skills rather than LVEF itself [50].
The following limitations have to be considered: first
the retrospective design of the study [51]; second it
covers a relatively long period during which both the
indications to surgery and the perioperative care may
have changed; third the lack of a long-term follow-up.
The study is monocentric and a validation group was
not available. The performance of the two models is
not optimal and they might be further improved in
larger multicentric studies; however, the cut-offs for
analyses were based on relevant clinical parameters
and were chosen according to international guidelines
[17]. We are aware that LVEF remains among the
strongest predictors of clinical outcome after cardiac
surgery, and we cannot exclude that other parameters,
that were not taken into consideration in the present
study, might play a relevant role. Finally, in some cases,
isolated CABG surgery was performed, although mitral
valve disease was also present: as we cannot provide
the rate of occurrence of this phenomenon, we can-
not exclude that it might have influenced our
results.
Conclusions
Moderate-to-severe left ventricular dysfunction is a
common finding in the general cardiac surgical popula-
tion. Patients with reduced LVEF undergoing cardiac
surgery have a high-risk of postoperative complications,
and higher mortality rates, however the surgery can be
performed with relatively low mortality rate. Among the
different cardiac surgical procedures patients with low
EF undergoing mitral valve surgery show the highest
mortality. Accurate preoperative evaluation and risk
stratification are of paramount importance in these
patients, and careful perioperative management is
mandatory.
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